AI-Integrated pDNA Vaccines for Personalized COVID-19 Protection
Legal Citation
Summary of the Inventive Concept
A novel system integrating AI, IoT, blockchain, and pDNA vaccines to provide personalized, adaptive, and secure COVID-19 protection
Background and Problem Solved
The original patent disclosed a pDNA vaccine against COVID-19, but it lacked the capability to provide personalized and adaptive protection. The new inventive concept addresses this limitation by combining the pDNA vaccine with AI-powered genomics analysis, IoT-enabled sensors, and blockchain-based patient data management, enabling real-time tracking and adaptation to emerging variants
Detailed Description of the Inventive Concept
The system consists of a pDNA vaccine, an AI-powered genomics analysis module that analyzes genomic data to identify personalized vaccine targets, an IoT-enabled sensor network that tracks vaccine efficacy and environmental factors, and a blockchain-based patient data management system that securely stores and shares patient data. The AI-driven protein design module engineers novel S protein variants for enhanced vaccine efficacy. The nanoparticle delivery system ensures targeted and efficient vaccine delivery. The blockchain-based platform enables secure sharing of SARS-CoV-2 genomic data and AI-powered predictive analytics for vaccine development
Novelty and Inventive Step
The new claims introduce the integration of AI, IoT, and blockchain technologies with pDNA vaccines, providing a novel and non-obvious solution for personalized and adaptive COVID-19 protection
Alternative Embodiments and Variations
Alternative embodiments may include the use of different AI algorithms, IoT sensor configurations, or blockchain platforms. Variations may include the integration of additional technologies, such as CRISPR gene editing or advanced materials, to further enhance vaccine efficacy and security
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the vaccine development and personalized medicine industries, with potential applications in pandemic preparedness, public health, and biodefense
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/215 |
| A | A61 | A61K9/0019 |
| A | A61 | A61P31/14 |
| C | C07 | C07K14/005 |
| A | A61 | A61K2039/53 |
| A | A61 | A61K2039/54 |
| A | A61 | A61K2039/545 |
| C | C12 | C12N2770/20022 |
| C | C12 | C12N2770/20034 |
| C | C12 | C12N2770/20071 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and molecular medicine, specifically vaccine design, genomic engineering, and personalized medical technologies with expertise in plasmid DNA (pDNA) vaccine development, bioinformatics, and advanced computational methods for protein design
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in molecular biology, bioinformatics, or bioengineering, possessing knowledge of vaccine development, computational protein design, genomic analysis techniques, and familiarity with emerging technologies like AI, blockchain, and IoT in medical applications
Obviousness Rationale
A PHOSITA would recognize that integrating computational technologies with pDNA vaccine design represents a natural progression of existing biotechnological approaches. The combination of AI-driven protein engineering, IoT tracking, and blockchain data management with established pDNA vaccine platforms follows predictable technological convergence patterns. These extensions represent incremental innovations that leverage known techniques to enhance vaccine personalization and monitoring capabilities.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,621 |
|---|---|
| Title | Synthetic pDNA vaccines against COVID-19 |
| Assignee(s) | Imam Abdulrahman Bin Faisal University |